1. Executive Summary (Confidence: High)

Mybacs® has established itself as a leading force in the European microbiome health market, bridging the gap between nutritional supplements and precision medicine. Founded in 2018, the company offers a suite of personalized "biotics" (pro-, pre-, and postbiotics) designed to address specific health goals ranging from metabolic balance to dermatological health. A key differentiator for mybacs is its commitment to scientific rigor, utilizing advanced metabolic modeling (MCMMs) and "digital twin" simulations to predict the success of probiotic interventions with high accuracy. With a loyal customer base of over 250,000 and a 90% subscription retention rate, mybacs is effectively scaling its direct-to-consumer (D2C) model across Switzerland, Germany, and Spain. The 2026 outlook emphasizes further clinical validation and the integration of cutting-edge AI to refine personalized health routines.